XOMA

XOMA Royalty Corporation · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website xoma.com
Employees(FY) 12
ISIN US98419J2069

Performance

-3.21%

-9.87%

-9.11%

+21.6%

+46.65%

YTD

+48.09%

Profile

XOMA Corporation operates as a biotech royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets. The company was incorporated in 1981 and is headquartered in Emeryville, California.

Advanced Technical Analysis

Technical Analysis of XOMA 2024-12-20

The stock indicators present a mixed sentiment, with a bearish Moving Average Score of 23, a neutral Oscillators Score of 60, and a neutral Technical Score of 41. This combination suggests a cautious outlook, as the bearish trend in moving averages may counterbalance the more favorable oscillator readings, indicating potential volatility ahead.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of XOMA

Stock Rank

Recent News & Updates

2024-12-18 18:30
XOMA Royalty Declares Quarterly Preferred Stock Dividends(Globenewswire)
2024-12-01 18:30
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio(Globenewswire)
2024-11-10 23:00
What Makes XOMA Royalty (XOMA) a New Buy Stock(Yahoo Finance)
2024-11-06 20:00
XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates(Yahoo Finance)
2024-11-06 18:52
XOMA Royalty: Q3 Earnings Snapshot(Yahoo Finance)
2024-11-06 18:30
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities(Globenewswire)
2024-10-21 20:00
Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash(Businesswire)
2024-10-21 20:00
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience(Globenewswire)
2024-09-22 18:30
Zevra's MIPLYFFA (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)(Globenewswire)
2024-09-22 17:30
XOMA Royalty Declares Quarterly Preferred Stock Dividends(Globenewswire)
2024-09-03 19:30
XOMA Royalty to Present at Upcoming Investor Conferences in September(Globenewswire)
2024-08-12 20:45
XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates(Yahoo Finance)
2024-08-12 19:39
XOMA Royalty: Q2 Earnings Snapshot(Yahoo Finance)
2024-08-12 19:30
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities(Globenewswire)
2024-07-17 16:08
Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains?(Yahoo Finance)
2024-06-20 19:54
Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?(Zacks)
2024-06-19 19:30
XOMA Declares Quarterly Preferred Stock Dividends(Globenewswire)
2024-06-11 19:30
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher(Globenewswire)
2024-06-11 18:00
3 Crazy Good Stocks to Buy With $500 Right Now(Investorplace)
2024-05-13 19:30
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ(Globenewswire)
2024-05-10 03:18
XOMA Corp (XOMA) Q1 2024 Earnings: Misses Revenue Estimates, Reports Lower Net Loss(Yahoo Finance)
2024-05-09 01:55
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024(Investorplace)
2024-05-08 20:00
Xoma: Q1 Earnings Snapshot(Yahoo Finance)
2024-05-08 19:30
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities(Globenewswire)
2024-05-06 22:00
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release(Zacks)
2024-04-29 19:30
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO (clindamycin phosphate) Vaginal Gel 2%(Globenewswire)
2024-04-24 19:30
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)(Globenewswire)
2024-04-23 21:00
Actym Therapeutics Appoints Thomas Smart as CEO(Prnewswire)
2024-04-02 21:00
XOMA Corporation Announces Closing of Tender Offer(Globenewswire)
2024-03-20 19:30
XOMA Declares Quarterly Preferred Stock Dividends(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.